Last reviewed · How we verify
Controlled Release Morphine
Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and provide analgesia.
Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception and provide analgesia. Used for Moderate to severe chronic pain, Cancer pain, Post-operative pain.
At a glance
| Generic name | Controlled Release Morphine |
|---|---|
| Sponsor | Nova Scotia Health Authority |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (μ-opioid receptor) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Morphine is a mu-opioid receptor agonist that modulates pain signaling by binding to opioid receptors in the brain, spinal cord, and peripheral tissues. The controlled-release formulation provides sustained drug delivery over an extended period, allowing for less frequent dosing compared to immediate-release formulations. This mechanism produces analgesia, sedation, and other opioid effects through activation of inhibitory pathways that reduce pain transmission.
Approved indications
- Moderate to severe chronic pain
- Cancer pain
- Post-operative pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Vomiting
- Respiratory depression
- Physical dependence
Key clinical trials
- A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy (PHASE3)
- Opioid-Sparing Joint Replacement (PHASE3)
- Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery (NA)
- Clinical Decision Support to Improve System Naloxone Co-prescribing
- Effect of Stress Ball During Chest Tube Removal After Open Heart Surgery (NA)
- Erector Spinae Plane Block in Lumbar Release Surgery (NA)
- Opioid Use After Laparoscopic Salpingectomy (PHASE4)
- Efficacy of Methylprednisolone for Pain Control After ACL Repair (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Controlled Release Morphine CI brief — competitive landscape report
- Controlled Release Morphine updates RSS · CI watch RSS
- Nova Scotia Health Authority portfolio CI